Heslop HE - Search Results

1

Engineered off-the-shelf therapeutic T cells resist host immune rejection.

Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Mo F, et al. Among authors: heslop he. Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13. Nat Biotechnol. 2021. PMID: 32661440 Free PMC article.

2

Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT.

Rencher SD, Hanif I, Heslop HE, Turner VE, Brenner MK, Hurwitz JL. Rencher SD, et al. Among authors: heslop he. Bone Marrow Transplant. 1992 Dec;10(6):521-7. Bone Marrow Transplant. 1992. PMID: 1490202

3

Immunotherapy of leukemia.

Brenner MK, Heslop HE. Brenner MK, et al. Among authors: heslop he. Leukemia. 1992;6 Suppl 1:76-9. Leukemia. 1992. PMID: 1548941 Review.

4

Graft-versus-host reactions and bone-marrow transplantation.

Brenner MK, Heslop HE. Brenner MK, et al. Among authors: heslop he. Curr Opin Immunol. 1991 Oct;3(5):752-7. doi: 10.1016/0952-7915(91)90108-d. Curr Opin Immunol. 1991. PMID: 1836732

5

Possible mechanism of action of interferon alpha in chronic B-cell malignancies.

Heslop HE, Brenner MK, Ganeshaguru K, Hoffbrand AV. Heslop HE, et al. Br J Haematol. 1991 Oct;79 Suppl 1:14-6. doi: 10.1111/j.1365-2141.1991.tb08111.x. Br J Haematol. 1991. PMID: 1931702 Review.

6

Graft versus leukaemia effects after marrow transplantation in man.

Brenner MK, Heslop HE. Brenner MK, et al. Among authors: heslop he. Baillieres Clin Haematol. 1991 Jul;4(3):727-49. doi: 10.1016/s0950-3536(09)90010-5. Baillieres Clin Haematol. 1991. PMID: 1958889 Review.

7

Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.

Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, Brenner MK. Gottlieb DJ, et al. Among authors: heslop he. Br J Haematol. 1990 Aug;75(4):499-505. doi: 10.1111/j.1365-2141.1990.tb07789.x. Br J Haematol. 1990. PMID: 2119792

8

In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation.

Heslop HE, Price GM, Prentice HG, Cordingley FT, Webster AD, Hoffbrand AV, Brenner MK. Heslop HE, et al. J Immunol. 1988 May 15;140(10):3461-6. J Immunol. 1988. PMID: 3283234

9

XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.

Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Koehler M, et al. Among authors: heslop he. Bone Marrow Transplant. 1994 May;13(5):571-5. Bone Marrow Transplant. 1994. PMID: 7519937

10

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Smith CA, et al. Among authors: heslop he. J Hematother. 1995 Apr;4(2):73-9. doi: 10.1089/scd.1.1995.4.73. J Hematother. 1995. PMID: 7633844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

415 results

Search Page